Hepatocellular carcinoma (HCC) is a primary tumor of the liver, which usually develops in the chronic liver disease, particularly in patients with chronic hepatitis Band C. Evaluating stages according to the BCLC (Barcelona Clinic Liver Cancer) system have led to a better prediction of prognosis and to a most appropriate treatment approach. Although the mainstay of therapy is surgical resection but the maioritv of oatients are not eliaible because of tumor extent or underlvina liver dvsfunction. In these cases, many studies have demonstrated that sorafenib is effective in the treatment of unresectable hepatocellular carcinoma (HCC). Objective: To evaluate the effectiveness of sorafenib in hepatocellular carcinoman treatment. Subiects and methods: A retrospective descriotive studv on 36 chronic liver disease patients. Results: The overall survival time of 36 HCC patients was 9.6 months and it was affected by liver function. The most common side effects were hand-foot svndrome (19.4 percent), diarrhea (8.3 percent), alooecia (8.3 percent), hypertension (2.8 percent) and almost its were mild grade. Conclusion: Sorafenib was demonstrated to significantly increase the survival of patients in HCC treatment with manageable side effects.